LYON, France--(BUSINESS WIRE)-- Regulatory News:
POXEL SA (Paris:POXEL) (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announced its cash position and its turnover for the fiscal year 2015.
As of December 31st, 2015, the cash and cash equivalents amounted to €42.4 million* compared to €10.3 million on December 31st, 2014.
The 2015 revenues resulting from collaboration, licensing and other agreements amounted €60,000.
These figures are consistent with the Company’s expectations and its growth strategy, which remains focused on the clinical development of its diabetes drug candidates Imeglimin and PXL770.
*unaudited
Next financial press release: Year Full-Year Financial Statement, March 31st, 2015
About Poxel
Poxel uses its unique development expertise in
metabolism to advance a pipeline of truly novel products currently
focused on type 2 diabetes. Our first-in-class lead product, Imeglimin,
targeting mitochondrial dysfunction, has successfully completed Phase 2
development in the US and EU and has entered clinical development in
Japan. We are advancing our second program, PXL770, a direct AMPK
activator, through clinical proof-of-concept. We will generate further
growth through strategic partnerships and pipeline development.
(Euronext: POXEL, www.poxel.com)
View source version on businesswire.com: http://www.businesswire.com/news/home/20160128005875/en/
Investor relations / Media - EU/US
MacDougall Biomedical
Communications
Gretchen Schweitzer or Stephanie May, + 49 89 2424
3494 or + 49 172 861 8540
smay@macbiocom.com
or
Investor
relations / Media - France
NewCap
Florent Alba/Nicolas
Mérigeau
+ 33 1 44 71 98 55
poxel@newcap.fr
Source: Poxel
Released January 28, 2016